An Evaluation of Psoriasis Patient Perceptions and Understanding of Biosimilars: A Canadian Survey Comparing Biologic and Nonbiologic Users

Abstract

Get full access to this article

View all access options for this article.

References

Strober

Armour

Romiti

et al . Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol. 2012;66:317-322.

Barsell

Rengifo-Pardo

Ehrlich

A survey assessment of US dermatologists’ perception of biosimilars. J Drugs Dermatol JDD. 2017;16:612-615.

Cohen

Puig

et al . Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017.

Fact Sheet: Subsequent Entry Biologics in Canada, Policy and Promotion Division, Centre for Policy and Regulatory Affairs Biologics and Genetic Therapies Directorate Health Canada. 2009. https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/biosimilars-biosimilaires-qa-qr-eng.pdf. Accessed July 1, 2017.

Calvo

Zuñiga

The US approach to biosimilars: the long-awaited FDA approval pathway. BioDrugs Clin Immunother Biopharm Gene Ther. 2012;26:357-361.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.44 MB